PostersScientific Publications MaaT034, a new co-cultured microbiome ecosystem therapy candidate, safely colonizes the gastro-intestinal tract of germ-free mice to restore a healthy gut physiology and stimulates immunity MaaT PharmaApril 4, 2025
PostersScientific Publications Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from Early Access Program in Europe MaaT PharmaDecember 9, 2024
PostersScientific Publications MaaT033 to ensure optimal intestinal microbiota to improve survival of patients receiving allo-HSCT: PHOEBUS trial MaaT PharmaDecember 2, 2024
PostersScientific Publications PHOEBUS Trial: an international, randomized, double-blind, multicenter phase IIb study evaluating MaaT033, oral allogeneic fecal microbiotherapy, in patients undergoing allo-HSCT to improve overall survival. SEHH Congress (Spanish only) MaaT PharmaDecember 2, 2024
PostersScientific Publications Evaluation of a new co-cultured Microbiome Ecosystem Therapy candidate (MaaT034) for clinical testing in combination with immune checkpoint inhibitors in solid tumors MaaT PharmaOctober 22, 2024
PostersScientific Publications Pooling of faecal material results in standardized and high taxonomic and functional richness microbiotherapy products MaaT PharmaJuly 22, 2024
PostersScientific Publications Safety, tolerability and gut microbIota AnalysiS of an Oral microbiotherapy in amyotrophic lateral sclerosis; an open-label phase 1b pilot trial MaaT PharmaJune 7, 2024
PostersScientific Publications A Multicentre, Randomized, Double-Blinded, Phase 2b Study Evaluating The Efficacy And Safety Of MaaT033, an Oral, Pooled Microbiome Ecosystem Therapy In Patients Undergoing Allogenic Hematopoietic Cell Transplantation to Improve Overall Survival: the PHOEBUS trial MaaT PharmaMarch 25, 2024
PostersScientific Publications Evaluation of a new co-cultured microbiome ecosystem therapy candidate (MaaT034) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors MaaT PharmaMarch 19, 2024
PostersScientific Publications A Multicentre, Randomized, Double-Blinded, Phase 2b Study Evaluating The Efficacy And Safety Of MaaT033, an Oral, Pooled Microbiome Ecosystem Therapy In Patients Undergoing Allogenic Hematopoietic Cell Transplantation to Improve Overall Survival: the PHOEBUS trial MaaT PharmaNovember 13, 2023
